Celltrion's Herzuma (Courtesy of Celltrion) South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flagship cancer treatments in Brazil and Guatemala.
This is the fifth consecutive year that Celltrion has won the trastuzumab biosimilar supply contract in Brazil, the biggest pharmaceutical market in Latin America. It has snagged a contract there since 2020, a year after entering the market.
As government tenders account for 97% of Brazil’s trastuzumab market, Celltrion’s successful bid is expected to effectively secure its dominance in the country, ensuring stable revenue for the Korean biotech company in the market this year.
Following the latest wins, which underscore Celltrion’s growing dominance in Latin America’s oncology biosimilars market, the Korean biosimilar giant plans to introduce other medicines in the region to extend its growth streak.
It plans to roll out the world’s only subcutaneous formulation of infliximab, Remsima SC, and the autoimmune disease treatment Yuflyma (adalimumab) in Latin America to expand its lineup in the region.
It will also seek to foray into other countries in the region.
We use cookies to provide the best user experience. By continuing to browse this website, you will be considered to accept cookies. Please review our Privacy Policy to learn our cookie policy.